Telix Pharmaceuticals TLX Institutional Ownership

Updated Oct 5, 2026

Telix Pharmaceuticals Ltd (NASDAQ:TLX) had 62 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Their combined stake equaled 0.94% of outstanding shares in Q2 2026, up from 0.76% in Q1 2026.
• Total shares held in Telix Pharmaceuticals rose 23.90% versus Q1 2026, while the number of holders rose 226.32% versus Q2 2025.
• Among the 62 holders of Telix Pharmaceuticals, 47 added to their positions, 7 reduced their stakes and 8 left their positions unchanged.
• The aggregate institutional position in Telix Pharmaceuticals was 3.18Mn shares at the end of Q2 2026, up 613.36K from the prior quarter and up 2.77Mn from a year earlier.
• As of June 30, 2026, FMR LLC held the largest stake in Telix Pharmaceuticals with 561.21K shares, or 0.17% of shares outstanding.
• The largest position increases in TLX for Q2 2026 were by UBS Group AG (+102.4K shares), XY Capital Ltd (+58.74K shares), Morgan Stanley (+49.54K shares), XTX Topco Ltd (+42.77K shares) and Vanguard Personalized Indexing Management, LLC (+25.74K shares).
• Holders that trimmed the most shares of Telix Pharmaceuticals in Q2 2026 while keeping a position were Portolan Capital Management, LLC (-515.84K shares), Raiffeisen Bank International AG (-15K shares), Mariner, LLC (-6.36K shares), Lazard Asset Management LLC (-5.71K shares) and Vident Advisory, LLC (-4.7K shares).
• Per Business Quant, the top 10 investors in TLX for the quarter ended June 30, 2026 were FMR LLC (561.21K shares), Lazard Asset Management LLC (284.21K shares), Portland Investment Counsel Inc. (266.2K shares), Private Advisor Group, LLC (197.25K shares), Marshall Wace, LLP (189.19K shares), Morgan Stanley (165.98K shares), Integrated Wealth Concepts LLC (164.4K shares), Hennion & Walsh Asset Management, Inc. (150.14K shares), UBS Group AG (134.7K shares) and Blair William & Co (122.98K shares).